Penumbra
0
Funds holding %
of 6,780 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]
17% more call options, than puts
Call options by funds: $68.2M | Put options by funds: $58.5M
5% more capital invested
Capital invested by funds: $6.45B [Q2] → $6.79B (+$336M) [Q3]
2.77% less ownership
Funds ownership: 92.66% [Q2] → 89.89% (-2.77%) [Q3]
4% less funds holding
Funds holding: 339 [Q2] → 327 (-12) [Q3]
19% less first-time investments, than exits
New positions opened: 51 | Existing positions closed: 63
29% less repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 138
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$222
9%
downside
Avg. target
$241
1%
downside
High target
$270
11%
upside
11 analyst ratings
11 positive
100%
0 neutral
0%
0 negative
0%
BTIG Ryan Zimmerman 45% 1-year accuracy 15 / 33 met price target | 11%upside $270 | Buy Maintained | 26 Nov 2024 |
Piper Sandler Matt O'Brien 71% 1-year accuracy 24 / 34 met price target | 3%upside $250 | Overweight Maintained | 20 Nov 2024 |
Piper Sandler Matt O'Brien 71% 1-year accuracy 24 / 34 met price target | 4%downside $235 | Overweight Maintained | 31 Oct 2024 |
Baird David Rescott 92% 1-year accuracy 11 / 12 met price target | 2%upside $248 | Outperform Maintained | 31 Oct 2024 |
Piper Sandler Matt O'Brien 71% 1-year accuracy 24 / 34 met price target | 8%downside $225 | Overweight Reiterated | 18 Oct 2024 |
Financial journalist opinion
Based on 9 articles about PEN published over the past 30 days
Positive
Zacks Investment Research
1 hour ago
Is Penumbra Stock a Smart Buy for Your Portfolio Right Now?
PEN stays on investors' radars due to its robust portfolio expansion and international growth plans.
Positive
Zacks Investment Research
3 days ago
GMED vs. PEN: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
Positive
Zacks Investment Research
3 days ago
Why Is Penumbra (PEN) Up 6.7% Since Last Earnings Report?
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
Positive
Zacks Investment Research
6 days ago
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
1 week ago
3 Reasons Growth Investors Will Love Penumbra (PEN)
Penumbra (PEN) possesses solid growth attributes, which could help it handily outperform the market.
Neutral
PRNewsWire
1 week ago
Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
ALAMEDA, Calif. , Nov. 20, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024.
Positive
Zacks Investment Research
3 weeks ago
Here is Why Growth Investors Should Buy Penumbra (PEN) Now
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Positive
Zacks Investment Research
3 weeks ago
Here's Why Penumbra (PEN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Neutral
PRNewsWire
4 weeks ago
New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options
Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system ALAMEDA, Calif. , Nov. 5, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra's computer assisted vacuum thrombectomy (CAVT™) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other treatment options.
Positive
Zacks Investment Research
1 month ago
Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market
The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business.
Charts implemented using Lightweight Charts™